Use of TNFα inhibitor for treatment of psoriasis
AssigneeAbbVie Biotechnology Ltd.
InventorsRebecca S. Hoffman, Mark Weinberg, Lori K. Taylor, Elliot K. Chartash, Philip Yan, George R. Granneman
Life of this patent
Estimating the term…
Abstract
The invention describes methods of treating erosive polyarthritis comprising administering a TNFα antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNFα antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
Claims8
A method for treating moderate to severe chronic plaque psoriasis, comprising subcutaneously administering to an adult patient having moderate to severe chronic plaque psoriasis a first dose of 80 mg of adalimumab, followed by 40 mg of adalimumab every other week starting one week after said first dosing, wherein the patient achieves at least Psoriasis Area and Severity Index (PASI) 90 response at week 12 of the treatment.
A method for treating moderate to severe chronic plaque psoriasis, comprising subcutaneously administering to an adult patient having moderate to severe chronic plaque psoriasis an initial dose of 80 mg of adalimumab, followed by 40 mg of adalimumab every other week starting one week after said initial dosing, wherein the patient achieves at least PASI 75 response at week 24 of the treatment.
A method for treating moderate to severe chronic plaque psoriasis, comprising subcutaneously administering to an adult patient having moderate to severe chronic plaque psoriasis an initial dose of 80 mg of adalimumab, followed by 40 mg of adalimumab every other week starting one week after said initial dosing, wherein when said method is used to treat a population of patients with moderate to severe chronic plaque psoriasis, at least 47% of said patients achieve at least PASI 75 response at week 12 of the treatment.
A method for treating moderate to severe chronic plaque psoriasis, comprising subcutaneously administering to an adult patient having moderate to severe chronic plaque psoriasis an initial dose of 80 mg of adalimumab, followed by 40 mg of adalimumab every other week starting one week after said initial dosing, wherein when said method is used to treat a population of patients with moderate to severe chronic plaque psoriasis, at least 53% of said patients achieve at least PASI 75 response at week 24 of the treatment.
Dependencies are inferred from the claim text.